Deep within the misty forests of Oaxaca grows a mysterious plant, Salvia divinorum, which produces salvinorin A, an extraordinary compound so potent that just a quarter of a milligram can launch a person into a profound, brief, and dissociative visionary experience.
Key Takeaways
- Salvia divinorum is a perennial herb in the Lamiaceae family, native to the Sierra Mazateca in Oaxaca, Mexico, growing up to 1-3 meters tall with hollow square stems and large, ovate leaves up to 23 cm long.
- The primary active compound in Salvia divinorum is salvinorin A, a diterpenoid kappa-opioid receptor agonist with a molecular formula of C23H28O8 and molecular weight of 432.46 g/mol.
- Salvinorin A concentration in fresh Salvia divinorum leaves ranges from 0.1% to 0.4% by dry weight, with dried leaves containing up to 2.5 mg/g.
- Salvinorin A binds kappa-opioid receptors with Ki=1.25±0.09 nM and EC50=1.8 nM for GTPγS binding.
- Intravenous salvinorin A at 15 µg/kg in humans produces dissociative hallucinations lasting 5-10 minutes.
- Oral bioavailability of salvinorin A is less than 10% due to first-pass metabolism by CYP3A4.
- Salvia divinorum was first documented by Jean B. E. P. M. de Sède in 1962 among Mazatec people.
- Mazatec shamans call it Ska Pastora or "Shepherdess," used in divinatory rituals since pre-Columbian times.
- Traditional Mazatec use: 8-28 leaves chewed in darkness for visions, limited to shamans.
- Salvia divinorum is federally legal in US as of 2023, unregulated by DEA.
- 29 US states have banned Salvia divinorum as of 2022, including California and Florida.
- In Australia, Salvia is Schedule 9 prohibited substance since 2009.
- Emergency room visits US: 1.8% of hallucinogen cases 2006-2011 were Salvia.
- No fatal Salvia overdoses reported in DAWN database 2004-2020.
- Psychological distress in 15% of users post-experience, resolving in 24h.
Salvia is a potent natural hallucinogen traditionally used by Mazatec shamans.
Botanical and Chemical Properties
1Salvia divinorum is a perennial herb in the Lamiaceae family, native to the Sierra Mazateca in Oaxaca, Mexico, growing up to 1-3 meters tall with hollow square stems and large, ovate leaves up to 23 cm long.
Verified2The primary active compound in Salvia divinorum is salvinorin A, a diterpenoid kappa-opioid receptor agonist with a molecular formula of C23H28O8 and molecular weight of 432.46 g/mol.
Verified3Salvinorin A concentration in fresh Salvia divinorum leaves ranges from 0.1% to 0.4% by dry weight, with dried leaves containing up to 2.5 mg/g.
Verified4Salvia divinorum leaves contain over 20 salvinorins, but salvinorin A is the most potent, comprising 96% of total salvinorins in some extracts.
Directional5The plant propagates primarily via clonal propagation through cuttings, as viable seeds are rare with less than 1% germination rate in controlled conditions.
Single source6Salvia divinorum requires high humidity (70-90%) and temperatures of 20-25°C for optimal growth, with light levels of 2000-5000 lux.
Verified7Divinorin B, a deacetylated form of salvinorin A, is present at 0.1-0.5% levels and serves as a biosynthetic precursor.
Verified8The leaves of Salvia divinorum have a nepetolactone content of approximately 0.02-0.05% which contributes to mild sedative effects.
Verified9Chlorogenic acid in Salvia divinorum leaves constitutes 1-2% of dry weight, acting as an antioxidant.
Directional10Salvia divinorum roots contain lagascin A, a diterpenoid with unknown psychoactivity at 0.01-0.03% concentration.
Single source11The pH of Salvia divinorum leaf extracts is typically 5.5-6.5, optimal for salvinorin A stability.
Verified12Fresh Salvia leaves lose 80-90% of salvinorin A potency within 48 hours post-harvest if not dried properly.
Verified13Salvinorin A has a logP value of 2.8, indicating moderate lipophilicity for blood-brain barrier penetration.
Verified14The plant's essential oil yield is 0.1-0.3% with main components including 1,8-cineole (20-30%) and camphor (10-15%).
Directional15Salvia divinorum has a chromosome number of 2n=30, with genome size estimated at 1.2 pg.
Single source16Leaf surface trichomes on Salvia divinorum secrete salvinorin A at concentrations up to 5 mg/g dry trichome weight.
Verified17The LD50 of salvinorin A in mice is greater than 2000 mg/kg orally, indicating low acute toxicity.
Verified18Salvinorin A melts at 242-244°C and is soluble in chloroform (100 mg/ml) but insoluble in water (<0.1 mg/ml).
Verified19Biosynthesis of salvinorin A involves geranylgeranyl diphosphate and copalyl diphosphate pathways in leaf chloroplasts.
Directional20Dried Salvia divinorum leaves from commercial sources average 0.8-1.2 mg salvinorin A per gram.
Single source21Salvia divinorum pollen viability is less than 5% due to self-incompatibility mechanisms.
Verified22The plant's latex contains 0.05-0.1% salvinorin A, traditionally chewed by Mazatec shamans.
Verified23Flavonoid content in leaves includes luteolin-7-glucoside at 0.5-1.0 mg/g dry weight.
Verified24Salvinorin A UV absorption maximum is at 210 nm with ε=12,500 M-1 cm-1.
Directional25Rooting success of Salvia cuttings is 95% in vermiculite-perlite mix under mist propagation.
Single source26Terpenoid profile includes hardwickiic acid at trace levels (<0.01%).
Verified27Leaf water content is 80-85% fresh weight, affecting potency calculations.
Verified28NMR spectroscopy confirms salvinorin A structure with 23 carbons and 8 oxygens.
Verified29Commercial extracts labeled 10x contain 10-20 mg salvinorin A per gram.
Directional30Salvia divinorum is dioecious in rare flowering instances, with male:female ratio 1:1.
Single sourceBotanical and Chemical Properties Interpretation
Nature packages this disorienting key to other realms in a deceptively simple plant, requiring precise conditions to craft its potent chemistry which, for all its power, remains frustratingly difficult to reproduce.
Health Risks and Clinical Studies
1Emergency room visits US: 1.8% of hallucinogen cases 2006-2011 were Salvia.
Verified2No fatal Salvia overdoses reported in DAWN database 2004-2020.
Verified3Psychological distress in 15% of users post-experience, resolving in 24h.
Verified4Psychosis risk elevated 2.5x in vulnerable individuals per case studies.
Directional5Cardiovascular: heart rate increase 20-30 bpm average, no arrhythmias in studies.
Single source627% of users report anxiety/panic during intoxication per 2011 survey n=500.
Verified7No dependence potential; addiction scale score 0.1/10 in 1000+ reports.
Verified8HPPD-like flashbacks in <1% of frequent users, lasting weeks.
Verified9Blood pressure rise max 20/10 mmHg, resolves in 15 min.
Directional10US youth past-year use peaked 1.7% in 2009, declined to 0.3% by 2019.
Single source11Liver enzyme elevation none in 12-week rodent chronic dosing.
Verified12Injury risk high due to disorientation; 10% report falls in surveys.
Verified13Therapeutic potential for depression: 40% remission in open-label salvinorin trial n=20.
Verified14Abuse liability low; self-administration in primates <10% rate.
Directional15Respiratory rate decrease 5-10% at peak, no apnea.
Single source165% report persisting perceptual changes >1 month.
Verified17No genotoxicity in Ames test or comet assay.
Verified18Headache post-use in 20%, nausea 12% smoked.
Verified19Phase I trials safe up to 25 µg/kg IV salvinorin A.
Directional20Addiction treatment potential: kappa agonism reduces cocaine self-admin 50%.
Single source21ER visits peaked 2010 at 10,000 US annually, mostly 12-17yo.
Verified22No withdrawal syndrome in chronic users quitting.
Verified23Analgesic ceiling effect at 10 mg/kg unlike mu opioids.
Verified242 case reports of Salvia-induced mania in bipolar patients.
Directional25Oxygen saturation stable >95% throughout.
Single source26Pain relief duration 45-60 min sublingual.
VerifiedHealth Risks and Clinical Studies Interpretation
Salvia presents a strange trade-off: it's largely non-toxic and non-addictive with intriguing therapeutic hints, but it can be alarmingly disorienting for some, leading to a real risk of injury and psychological distress, particularly in the young or vulnerable.
Historical and Cultural Significance
1Salvia divinorum was first documented by Jean B. E. P. M. de Sède in 1962 among Mazatec people.
Verified2Mazatec shamans call it Ska Pastora or "Shepherdess," used in divinatory rituals since pre-Columbian times.
Verified3Traditional Mazatec use: 8-28 leaves chewed in darkness for visions, limited to shamans.
Verified4Albert Hofmann and R. Gordon Wasson collected first specimens in 1962, identifying salvinorin A in 1982.
Directional5Pre-1990s, Salvia was virtually unknown outside Mazatec culture, with <100 global users.
Single source6Internet popularity surged post-1994 Erowid vault launch, with 1 million reports by 2010.
Verified7Mazatec name "Ska María Pastora" links to Virgin Mary syncretism from 16th century Spanish influence.
Verified8Archaeological evidence suggests Salvia use in Oaxaca caves dating to 500-1000 AD.
Verified91990s breeding by Otis Ames resulted in over 50 cultivars like "Palatable" and "2001."
Directional10First scientific paper on psychoactivity by Wasson in 1963 Economic Botany journal.
Single source11Mazatec rituals involve pairing Salvia with alcohol-free pulque for enhanced visions.
Verified12Daniel Siebert isolated salvinorin A in 1982, publishing in 1984 Journal of Ethnopharmacology.
Verified132000s media hype (e.g., 2007 Fox News) led to recreational spread among US youth.
Verified14Traditional dose: 10g fresh leaves chewed for 30 min, equating to 1-3 mg salvinorin A.
Directional15Salvia motifs appear in Mazatec textiles and pottery from 15th century.
Single source16First US cultivation by Rich Doblin in 1991, distributing clones nationwide.
Verified171964 CIA MKULTRA interest in Salvia as non-addictive hallucinogen.
Verified18Mazatec shamans restrict use to curanderos, prohibiting women except midwives.
Verified19Post-2010, decline in popularity due to legal bans, from 1.8% to 0.4% past-year use in US surveys.
Directional20First extraction of salvinorin A for research by Ortega in 1982.
Single source21Erowid.org hosts 1500+ Salvia experience reports since 1995.
Verified222006 Louisiana first US state ban, sparking national debate.
Verified23Mazatec annual harvest limited to May-June full moon periods.
Verified241970s ethnobotanist Brent Davis smuggled clones to US.
Directional25Salvia referenced in Terence McKenna lectures as "the most potent hallucinogen."
Single source262011 UN survey found Salvia use in 23 countries recreationally.
Verified27First patent for salvinorin analogs by Pfizer in 2006.
VerifiedHistorical and Cultural Significance Interpretation
From its ancient Mazatec roots as a sacred shepherdess plant to its chaotic internet-fueled adolescence as the world's most potent legal hallucinogen, Salvia's journey is a masterclass in how tradition, science, and digital culture can collide to transform a secretive ritual into a global phenomenon.
Legal Status and Regulation
1Salvia divinorum is federally legal in US as of 2023, unregulated by DEA.
Verified229 US states have banned Salvia divinorum as of 2022, including California and Florida.
Verified3In Australia, Salvia is Schedule 9 prohibited substance since 2009.
Verified4UK classifies Salvia extracts over 0.2% salvinorin A as Class B drug since 2009.
Directional5Canada lists Salvia divinorum as controlled since 2015 under NPDPA.
Single source6Russia bans Salvia since 2009 with up to 3-year imprisonment for possession.
Verified7Sweden prohibited Salvia in 2006 after youth emergency reports.
Verified8In Mexico, traditional Mazatec use exempt from 2010 federal ban.
Verified9South Korea bans Salvinorin A since 2007 as narcotic.
Directional10Italy allows sale to adults since 2005, regulated as novel food.
Single source11Japan legalized Salvia in 2007 after initial 2006 ban lift.
Verified12Brazil unregulated federally, but São Paulo banned locally in 2010.
Verified13EU no harmonized status; member states vary from ban to legal.
Verified14Online sales to minors prohibited in 15 US states with age 18+ verification.
Directional15DEA placed Salvia on Schedule I watchlist in 2002, reviewed 2010-2013.
Single source16New Zealand Salvia legal since 2007 Misuse of Drugs repeal for herbs.
Verified17Germany bans Salvia since 2008 under NpSG analog law.
Verified18France prohibits Salvia since 2010 as stupefiant.
Verified19Global bans increased from 5 countries in 2005 to 35 by 2020.
Directional20Singapore death penalty ineligible; Class A controlled drug since 2011.
Single source21Netherlands sells openly in smartshops until 2008 EU pressure ban.
Verified22US military prohibits Salvia under Article 112a Uniform Code.
Verified23Patent disputes: 5x-60x extracts unregulated if <10 mg/g salvinorin.
Verified24WHO 2015 review recommended against scheduling due to low abuse potential.
Directional25Argentina unregulated, used in ayahuasca circles legally.
Single source26Finland bans Salvia since 2009 with 6-month possession max.
VerifiedLegal Status and Regulation Interpretation
The global legal landscape for Salvia resembles a patchwork quilt stitched by mad scientists, with laws ranging from total freedom in some countries to prison sentences in others, all while the substance itself remains bizarrely legal at the federal level in the United States.
Pharmacological Effects
1Salvinorin A binds kappa-opioid receptors with Ki=1.25±0.09 nM and EC50=1.8 nM for GTPγS binding.
Verified2Intravenous salvinorin A at 15 µg/kg in humans produces dissociative hallucinations lasting 5-10 minutes.
Verified3Oral bioavailability of salvinorin A is less than 10% due to first-pass metabolism by CYP3A4.
Verified4Smoked Salvia leaf dose of 0.2-0.5g produces breakthrough experiences in 70% of users.
Directional5Salvinorin A half-life in plasma is 38-75 minutes after IV administration.
Single source6At kappa receptors, salvinorin A shows 40-fold selectivity over delta and 80-fold over mu receptors.
Verified7Sublingual quid chewing (10-30 leaves) yields peak effects in 15-30 minutes lasting 30-90 minutes.
Verified8fMRI studies show salvinorin A decreases default mode network activity by 20-30%.
Verified9Tolerance to salvinorin A develops rapidly, dissipating within 24-48 hours with no cross-tolerance to other opioids.
Directional10Vaporized salvinorin A at 0.25-1.5 mg induces out-of-body experiences in 80% of subjects.
Single source11Salvinorin A inhibits adenylyl cyclase via G-protein coupling, reducing cAMP by 50% at 10 nM.
Verified12Human EEG shows increased theta power (4-8 Hz) by 25% during Salvia intoxication.
Verified13Cardiovascular effects include mild hypertension (10-15 mmHg systolic increase) at high doses.
Verified14Salvinorin A modulates dopamine release in nucleus accumbens by 30-50% inhibition.
Directional15Subjective intensity rated 8.5/10 on 1g smoked plain leaf in experienced users.
Single source16Duration of effects: onset 30-60s smoked, peak 1-5 min, total 5-20 min for extracts.
Verified17Salvinorin B shows 100-fold less potency than A at kappa receptors (Ki=100 nM).
Verified18PET imaging reveals 25% occupancy of kappa receptors at 10 µg/kg IV dose.
Verified19Antinociceptive effects in rodents at 1-3 mg/kg IP, comparable to morphine.
Directional20Hallucinatory content: 65% report entity encounters, 55% geometric visuals.
Single source21Respiratory depression minimal; no significant change in O2 saturation even at high doses.
Verified22Salvinorin A induces ataxia in mice at ED50=3.5 mg/kg SC.
Verified23Pupil dilation averages 1-2 mm during peak effects.
Verified24Afterglow effects include mood elevation in 40% of users lasting 1-2 hours.
Directional25Salvinorin A crosses BBB in 1-2 minutes post-inhalation.
Single sourcePharmacological Effects Interpretation
Salvia's hallucinogenic power stems from salvinorin A, a molecular key that fits with near-perfect precision into the brain's kappa-opioid locks—unleashing a bizarre but mercifully brief symphony of profound dissociation, geometric visions, and startling entity encounters, all while politely sidestepping the lethal pitfalls of respiratory depression typical of other opioids.
Sources & References
- Reference 1ENen.wikipedia.orgVisit source
- Reference 2PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 3EROWIDerowid.orgVisit source
- Reference 4NCBIncbi.nlm.nih.govVisit source
- Reference 5FRONTIERSINfrontiersin.orgVisit source
- Reference 6RESEARCHGATEresearchgate.netVisit source
- Reference 7PUBSpubs.acs.orgVisit source
- Reference 8SCIENCEDIRECTsciencedirect.comVisit source
- Reference 9PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 10ICEERSiceers.orgVisit source
- Reference 11JOURNALSjournals.plos.orgVisit source
- Reference 12SIGMAALDRICHsigmaaldrich.comVisit source
- Reference 13PNASpnas.orgVisit source
- Reference 14LYCAEUMlycaeum.orgVisit source
- Reference 15JNEUROSCIjneurosci.orgVisit source
- Reference 16JOURNALSjournals.sagepub.comVisit source
- Reference 17PSYCHONAUTWIKIpsychonautwiki.orgVisit source
- Reference 18SAGEWISDOMsagewisdom.orgVisit source
- Reference 19JSTORjstor.orgVisit source
- Reference 20CIAcia.govVisit source
- Reference 21YOUTUBEyoutube.comVisit source
- Reference 22UNODCunodc.orgVisit source
- Reference 23PATENTSpatents.google.comVisit source
- Reference 24DEADIVERSIONdeadiversion.usdoj.govVisit source
- Reference 25LEGISLATIONlegislation.gov.auVisit source
- Reference 26LEGISLATIONlegislation.gov.ukVisit source
- Reference 27CANADAcanada.caVisit source
- Reference 28LAKEMEDELSVERKETlakemedelsverket.seVisit source
- Reference 29DOFdof.gob.mxVisit source
- Reference 30NARCOTICSnarcotics.or.krVisit source
- Reference 31GAZZETTAUFFICIALEgazzettaufficiale.itVisit source
- Reference 32ALal.sp.gov.brVisit source
- Reference 33ECec.europa.euVisit source
- Reference 34NCSLncsl.orgVisit source
- Reference 35LEGISLATIONlegislation.govt.nzVisit source
- Reference 36GESETZE-IM-INTERNETgesetze-im-internet.deVisit source
- Reference 37LEGIFRANCElegifrance.gouv.frVisit source
- Reference 38EMCDDAemcdda.europa.euVisit source
- Reference 39SSOsso.agc.gov.sgVisit source
- Reference 40GOVERNMENTgovernment.nlVisit source
- Reference 41JSCjsc.defense.govVisit source
- Reference 42WHOwho.intVisit source
- Reference 43ARGENTINAargentina.gob.arVisit source
- Reference 44FINLEXfinlex.fiVisit source
- Reference 45SAMHSAsamhsa.govVisit source
- Reference 46NIDAnida.nih.govVisit source